Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
29 stopped studies mapped to Malignant Soft Tissue Neoplasm of Uncertain Differentiation and descendants · 93% state a reason
Over the 29 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04204941 | Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced… | Phase 1 | terminated | Dec 19, 2019 | Epizyme, Inc. | FDA and Ipsen alignelment: Due to unfeasibility and the resulting inability to meet the required… | Safety / toxicity |
| NCT04530487 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or… | Phase 2 | terminated | Aug 28, 2020 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT01125449 | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | Phase 2 | withdrawn | May 18, 2010 | Situs Cancer Research Center | Awaiting response from FDA as to status of parenteral ascorbic acid manufactured by Bioniche… | Drug supply |
| NCT04965753 | FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors | Phase 1 | terminated | Jul 16, 2021 | Foghorn Therapeutics Inc. | Sponsor decision | Sponsor / business decision |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for…(TOASTIT) | Early Phase 1 | terminated | Dec 30, 2019 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT05355753 | A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or… | Phase 1 | terminated | May 2, 2022 | C4 Therapeutics, Inc. | High levels of BRD9 degradation did not result in sufficient efficacy in heavily pre-treated… | Efficacy / futility |
| NCT03604783 | Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors | Phase 1 | terminated | Jul 27, 2018 | Sumitomo Pharma America, Inc. | Sponsor's decision to terminate further development of the program. | Sponsor / business decision |
| NCT03132155 | QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma | Phase 2 | terminated | Apr 27, 2017 | NantPharma, LLC | Prematurely terminated due to lack of therapeutic effect | Other (stated, no rule matched) |
| NCT03670069 | Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas | Phase 1 | terminated | Sep 13, 2018 | Fred Hutchinson Cancer Center | The study was terminated early with 27 out of 28 planned subjects enrolled. This decision was… | Enrollment / accrual |
| NCT04901806 | Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors | Phase 1 | terminated | May 26, 2021 | Pyramid Biosciences | Sponsor terminated development of PBI-200 | Other (stated, no rule matched) |
| NCT04176016 | Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory… | Phase 1 | terminated | Nov 25, 2019 | OncoTherapy Science, Inc. | Some of the raw materials for the investigational drug are difficult to obtain and expensive. | Other (stated, no rule matched) |
| NCT04274023 | Study on TSR-042 in Advanced Clear Cell Sarcoma(ACCeSs) | Phase 2 | terminated | Feb 18, 2020 | Italian Sarcoma Group | Difficulty of enrollment | Enrollment / accrual |
| NCT04145700 | CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial… | Phase 1 / Phase 2 | terminated | Oct 31, 2019 | Eli Lilly and Company | Study terminated for meeting protocol specified futility criteria. | Efficacy / futility |
| NCT03399448 | NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | Phase 1 | terminated | Jan 16, 2018 | University of Pennsylvania | Sponsor has terminated trial to pursue other targets. | Other (stated, no rule matched) |
| NCT00140855 | A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma | Phase 2 | terminated | Sep 1, 2005 | Ludwig Institute for Cancer Research | Study discontinued due to poor accrual. | Enrollment / accrual |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or… | Phase 1 / Phase 2 | terminated | Nov 10, 2015 | National Cancer Institute (NCI) | Interim monitoring | Other (stated, no rule matched) |
| NCT05116800 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | Phase 2 | withdrawn | Nov 11, 2021 | Brown University | IND withdrawn | Other (stated, no rule matched) |
| NCT04906876 | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With… | Phase 2 | withdrawn | May 28, 2021 | Brown University | IND withdrawn | Other (stated, no rule matched) |
| NCT03880123 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | Phase 1 | withdrawn | Mar 19, 2019 | Matthew Ingham | Study will not proceed, no participants enrolled. | Enrollment / accrual |
| NCT02609984 | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab… | Phase 2 | terminated | Nov 20, 2015 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | This study did not meet the efficacy objective | Efficacy / futility |
| NCT03520959 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With… | Phase 3 | terminated | May 11, 2018 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Study was terminated due to sponsor's decision. | Sponsor / business decision |
| NCT02683148 | DHEA in Synovial Sarcoma Patients | Phase 1 | terminated | Feb 17, 2016 | Washington University School of Medicine | The trial did not show any positive effects. | Other (stated, no rule matched) |
| NCT01957709 | Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma | Early Phase 1 | terminated | Oct 8, 2013 | Fred Hutchinson Cancer Center | Enough samples were collected for data analysis. | Other (stated, no rule matched) |
| NCT03773510 | Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin(TRADITIONS) | Phase 3 | withdrawn | Dec 12, 2018 | Italian Sarcoma Group | Not approved by the coordinating Ethical Committee | Other (stated, no rule matched) |
| NCT02113826 | Pazopanib for Metastatic Alveolar Soft Part Sarcoma | Phase 2 | terminated | Apr 15, 2014 | Seoul National University Hospital | Low accrual rate | Enrollment / accrual |
| NCT01469975 | First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended…(SYNFRIZZ) | Phase 1 | terminated | Nov 10, 2011 | Centre Leon Berard | Too slow accrual. | Enrollment / accrual |
| NCT02059850 | NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced… | Phase 1 | withdrawn | Feb 11, 2014 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT01795430 | Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed… | N/A | withdrawn | Feb 20, 2013 | City of Hope Medical Center | No participants enrolled. | Enrollment / accrual |
| NCT01690871 | A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or… | Phase 2 | withdrawn | Sep 24, 2012 | Novartis Pharmaceuticals | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jan 7, 2026source: clinicaltrials